A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

Alaa Alkhalaf; Astrid Klooster; Willem van Oeveren; Ulrike Achenbach; Nanne Kleefstra; Robbert J. Slingerland; G. Sophie Mijnhout; Henk J. G. Bilo; Reinold O. B. Gans; Gerjan J. Navis; Stephan J. L. Bakker

doi:10.2337/dc09-2241

A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

Alaa Alkhalaf^*
, Astrid Klooster
, Willem van Oeveren
, Ulrike Achenbach
, Nanne Kleefstra
, Robbert J. Slingerland
, G. Sophie Mijnhout
, Henk J. G. Bilo
, Reinold O. B. Gans
, Gerjan J. Navis
, Stephan J. L. Bakker

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

86 Citations (Scopus)

Abstract

OBJECTIVE - To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.

RESEARCH DESIGN AND METHODS - Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).

RESULTS - Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P <0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.

CONCLUSIONS - In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.

Original language	English
Pages (from-to)	1598-1601
Number of pages	4
Journal	Diabetes Care
Volume	33
Issue number	7
DOIs	https://doi.org/10.2337/dc09-2241
Publication status	Published - Jul-2010

Keywords

HIGH-DOSE THIAMINE
DISEASE
DAMAGE

Access to Document

10.2337/dc09-2241

Handle.net

Persistent link

Cite this

Alkhalaf, A., Klooster, A., van Oeveren, W., Achenbach, U., Kleefstra, N., Slingerland, R. J., Mijnhout, G. S., Bilo, H. J. G., Gans, R. O. B., Navis, G. J., & Bakker, S. J. L. (2010). A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy. Diabetes Care, 33(7), 1598-1601. https://doi.org/10.2337/dc09-2241

@article{634d6a5ff42a4126afaa076ac98e13b5,

title = "A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy",

abstract = "OBJECTIVE - To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.RESEARCH DESIGN AND METHODS - Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).RESULTS - Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P <0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.CONCLUSIONS - In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.",

keywords = "HIGH-DOSE THIAMINE, DISEASE, DAMAGE",

author = "Alaa Alkhalaf and Astrid Klooster and \{van Oeveren\}, Willem and Ulrike Achenbach and Nanne Kleefstra and Slingerland, \{Robbert J.\} and Mijnhout, \{G. Sophie\} and Bilo, \{Henk J. G.\} and Gans, \{Reinold O. B.\} and Navis, \{Gerjan J.\} and Bakker, \{Stephan J. L.\}",

note = "Article",

year = "2010",

month = jul,

doi = "10.2337/dc09-2241",

language = "English",

volume = "33",

pages = "1598--1601",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "AMER DIABETES ASSOC",

number = "7",

}

TY - JOUR

T1 - A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

AU - Alkhalaf, Alaa

AU - Klooster, Astrid

AU - van Oeveren, Willem

AU - Achenbach, Ulrike

AU - Kleefstra, Nanne

AU - Slingerland, Robbert J.

AU - Mijnhout, G. Sophie

AU - Bilo, Henk J. G.

AU - Gans, Reinold O. B.

AU - Navis, Gerjan J.

AU - Bakker, Stephan J. L.

N1 - Article

PY - 2010/7

Y1 - 2010/7

N2 - OBJECTIVE - To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.RESEARCH DESIGN AND METHODS - Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).RESULTS - Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P <0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.CONCLUSIONS - In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.

AB - OBJECTIVE - To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.RESEARCH DESIGN AND METHODS - Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).RESULTS - Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P <0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.CONCLUSIONS - In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.

KW - HIGH-DOSE THIAMINE

KW - DISEASE

KW - DAMAGE

U2 - 10.2337/dc09-2241

DO - 10.2337/dc09-2241

M3 - Article

SN - 0149-5992

VL - 33

SP - 1598

EP - 1601

JO - Diabetes Care

JF - Diabetes Care

IS - 7

ER -

A Double-Blind, Randomized, Placebo-Controlled Clinical Trial on Benfotiamine Treatment in Patients With Diabetic Nephropathy

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this